doi: 10.1002/eji.1830240340.
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
Affiliations
- PMID: 8125142
- DOI: 10.1002/eji.1830240340
Item in Clipboard
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
Eur J Immunol.
1994 Mar.
Abstract
A number of cytolytic T lymphocyte (CTL) clones derived from several melanoma patients have been found to recognize a majority of melanomas from HLA-A2 patients. We have reported previously that two such CTL clones recognize a product of the tyrosinase gene that is presented by HLA-A2. Here we show that one of these CTL clones recognizes a peptide encoded by the first nine amino acids of the putative signal sequence of tyrosinase. The other CTL clone recognizes a different tyrosinase peptide corresponding to amino acids 368-376. Both peptides contain consensus motifs of HLA-A2 binding peptides.
Similar articles
-
Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.Cancer Res. 1999 Aug 15;59(16):4050-5. Cancer Res. 1999. PMID: 10463606
-
Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines.Biochem Soc Trans. 1995 Aug;23(3):681-6. doi: 10.1042/bst0230681. Biochem Soc Trans. 1995. PMID: 8566443 Review. No abstract available.
-
A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.Eur J Immunol. 1996 Jan;26(1):224-30. doi: 10.1002/eji.1830260135. Eur J Immunol. 1996. PMID: 8566071
-
Genes coding for tumor antigens recognized by human cytolytic T lymphocytes.J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):104-9. doi: 10.1097/00002371-199308000-00004. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8280701 Review.
-
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.Eur J Immunol. 1994 Dec;24(12):3038-43. doi: 10.1002/eji.1830241218. Eur J Immunol. 1994. PMID: 7805731
Cited by
-
Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.Pharmaceutics. 2022 Jul 11;14(7):1448. doi: 10.3390/pharmaceutics14071448. Pharmaceutics. 2022. PMID: 35890342 Free PMC article. Review.
-
Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy.Cancers (Basel). 2021 Dec 1;13(23):6061. doi: 10.3390/cancers13236061. Cancers (Basel). 2021. PMID: 34885172 Free PMC article. Review.
-
HLA-DRB1∗16:01 and HLA-DQB1∗05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.J Oncol. 2021 Sep 30;2021:3801143. doi: 10.1155/2021/3801143. eCollection 2021. J Oncol. 2021. PMID: 34630564 Free PMC article.
-
Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.Oncotarget. 2020 Sep 1;11(35):3315-3349. doi: 10.18632/oncotarget.27709. eCollection 2020 Sep 1. Oncotarget. 2020. PMID: 32934776 Free PMC article.
-
Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model.Vaccine. 2019 Aug 14;37(35):4947-4955. doi: 10.1016/j.vaccine.2019.07.018. Epub 2019 Jul 13. Vaccine. 2019. PMID: 31307876 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
